|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 田园学校/北京四中房山校区显示文摘北京,2010-2014这个占地4.5ha的新建公立中学位于北京西南五环外的一个新城的中心,是著名的北京四中的分校区。新学校是避免早期单一功能的郊区开发模式、提倡更加健康和可持续发展的新城计划的重要部分,对新近城市化的周边地区发展起着至关重要的作用。学校的功能空间被组织成上下两部分,并在其间插入花园。垂直并置的上部建筑和下部空间在"中间地带"(架空的夹层)以不同方式相互接触、支撑或连接,这既是营造空间的策略,也象征了新学校中正式与非正式教学空间的关系。 | 李虎 黄文菁 Daijiro Nakayama 叶青 张浩 周亭婷 Thomas Batzenschlager 张畅 Jotte Seghers 王一帆 于清波 苏圣亮 夏至 Spirit of Space | 2018 | 城市环境设计2018，0，5： | 4 |
| 2 | Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer显示文摘 | Ettinger DS Jotte R Lorigan P | | 0，，15： | 1 |
| 3 | Phase Ⅱ trial of nanoparticie albumin-bound paclitaxel,carboplatin,and bevacizumab in firstline patients with advanced nonsquamous non-small cell lung cancer 显示文摘 | Reynolds C Barrera D Jotte R | 2009 | J Thorac Oncol2009，4，12： | 1 |
| 4 | Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced non- squamous non-small cell lung cancer显示文摘 | Reynolds C Barrera D Jotte R | 2009 | J Thorac On- col2009，4，12： | 1 |
| 5 | Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer显示文摘 | Mark A. Socinski Robert N. Raju Thomas Stinchcombe Darren M. Kocs Linda S. Couch David Barrera Steven R. Rousey Janak K. Choksi Robert Jotte Debra A. Patt Phillip O. Periman Howard R. Schlossberg Charles H. Weissman Yunfei Wang Lina Asmar Sharon Pritchard | 2010 | Journal of Thoracic Oncology2010，，： | 1 |
| 6 | Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum- based chemotherapy显示文摘 | Jotte R Conkling P Reynolds C | 2011 | J Clin Oncol2011，29，3： | 1 |
| 7 | Phase II study of amrubicin as second-line therapy in patients with platinum- refractory small-cell lung cancer 显示文摘 | Ettinger DS Jotte R Lorigan P | 2010 | J ClinOncol2010，28，15： | 1 |
| 8 | Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum- based chemotherapy 显示文摘 | Jotte R Conkling P Reynolds C | 2011 | J Clin Onco12011，29，3： | 1 |
| 9 | Results of a randomized phase II trial of amrubicin(AMR)versus topotecan(Topo)in patients with extensive disease small cell lung cancer(ED-SCLC)sensitive to first-line platinum based chemotherapy显示文摘 | Jotte R Conkling P Reynolds C | 2009 | J Clin Oncol2009，，： | 1 |
| 10 | A phase 11 trial of single-agent amrubicin(AMR)in patients with extensive disease small cell lung cancer(ED-SCLC)that is refraetory or progressive within 90 days of completion of first-line platinum based chemotherapy显示文摘 | Ettinger DS Jotte RM Gupta V | 2008 | J Clin Oncol(Meeting Abstraets)2008，26，： | 1 |
| 11 | Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy 显示文摘 | Jotte R Conkling P Reynolds C | 2011 | J Clin Oncol2011，29，3： | 1 |
| 12 | Randomized phase Ill trial of amrubicin versus topotecan (Topo) as second- line treatment for small cell lung cancer (SCLC)显示文摘 | Jotte R Von Pawel J Spigel D R | 2011 | J Clin Oncol2011，29，15： | 1 |
| 13 | A phase Ⅱ trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer ( ED-SCLC ) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy 显示文摘 | Ettinger DS Jotte RM Gupta V | 2008 | J Clin Oncol2008，26，： | 1 |
| 14 | Randomized phase m trial of Amrubicin versus Topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC)显示文摘 | Jotte R Von Pawel J Spigel DR | 2011 | J Clin Oncol2011，，： | 1 |
| 15 | Randomized phase I1 trial of single-agent Amrubicin or Topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy显示文摘 | Jotte R Conkling P Reynolds C | 2011 | J Clin Oncol2011，29，3： | 1 |
| 16 | Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first- line platinum-based chemotherapy显示文摘 | Jotte R Conkling P Reynolds C | 2011 | J Clin Oncol2011，29，3： | 1 |
| 17 | Randomized phase Ⅲ trial of amrubicin versus topotecan (Topo) as second line treatment for small cell lung cancer (SCLC)显示文摘 | Jotte R Von Pawel J Spigel DR | | 0，，： | 1 |
| 18 | A phase II trail of single agent amrubicin (AMR) in patients with ED-SCLC that is refractory or progressive within 90 days of completion of first-line platinum based chemotheraphy显示文摘 | Ettinger DS Jotte RM Gupta V | 2008 | J Olin Oncol2008，26，15： | 1 |
| 19 | Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinumbased chemotherapy显示文摘 | Jotte R Conkling P Reynolds C | | 0，，03： | 1 |
| 20 | Phase II trial of nanopartide albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer显示文摘 | Reynolds C Barrera D Jotte R | 2009 | J Thorac Oncol2009，4，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员